Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
SCLC, Small Cell Lung Cancer

Combating Small Cell Lung Cancer with Upfront Immunotherapy Options

Posted on March 23, 2020
Post Views: 1,020

SCLC, Small Cell Lung CancerLung Cancer is the second most common form of cancer worldwide. Small-cell lung cancer (SCLC) represents about 10% to 15% of all lung cancers. It is a form of neuroendocrine tumor, classified into limited and extensive-stage disease. Chemotherapy remains the standard line of treatment for SCLC. SCLC remains challenging for treatment as it has aggressive nature and has limited therapy advancements. In the recent years, immunotherapy has transformed the way patients can be treated with this disease. The clinical trials combining immunotherapy and drugs help to boost the immune system to person and thus, helping in fighting the lung cancer. Immunotherapy is the use of medicines for stimulating the person’s own immune system to recognize and then destroy the cancer cells effectively.

Dr. Jason Niu, a thoracic oncologist and director of the Lung Cancer Program at the Banner MD Anderson Cancer Center, said in an interview with OncLive®, a sister publication of CURE®, “Essentially, these (combinations) are game-changers that have transformed how we treat patients with extensive-stage SCLC. We have a new standard of care.” Niu has specifically referred to two clinical trials, IMpower133 and CASPIAN. These both have showed survival benefits for the lung cancer patients. He has also explained that the follow-up from the trial has been short and thus, it is vital to follow the patients to see the long-term survival benefits.

Immunotherapy for Lung CancerThose patients where lung cancer progresses following the initial treatments: Dr. Jason Niu has explained that other immunotherapy agents like Keytruda (pembrolizumab), Opdivo (nivolumab) and Yervoy (ipilimumab) can also be used. Lurbinectedin is a new chemotherapy compound and has shown encouraging overall survival results. The trial included 105 patients with SCLC showed up to 45% response rate and an 11-month median overall survival.

Also, biomarkers are required in order to better inform which patients are most likely to respond to immunotherapy.

The information shared in this blog is for educational purposes only and is not a substitute for medical advice. If you face any issues, contact your healthcare practitioner immediately.

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,303)
  • Lung Cancer: Symptoms and Treatment (5,625)
  • What is Non-Small-Cell Lung Cancer? (5,531)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025
  • Lung Cancer Screening Is Beneficial For Non-Smokers As Well April 28, 2025
  • Understanding The Stage 0 Lung Cancer April 21, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha. Privacy Policy
%d